Zacks Investment Research upgraded shares of Sientra (NASDAQ:SIEN) from a sell rating to a hold rating in a report published on Saturday, Zacks.com reports.

According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “

SIEN has been the topic of a number of other reports. Maxim Group increased their price objective on shares of Sientra from $5.00 to $8.00 in a research note on Thursday, June 11th. Canaccord Genuity reduced their price objective on shares of Sientra from $9.00 to $5.00 and set a buy rating on the stock in a research note on Friday, May 15th. Craig Hallum reduced their price objective on shares of Sientra from $14.00 to $9.00 and set a buy rating on the stock in a research note on Thursday, March 12th. Stephens reduced their price objective on shares of Sientra from $10.00 to $5.00 and set an overweight rating on the stock in a research note on Monday, March 23rd. Finally, SVB Leerink reduced their price objective on shares of Sientra from $6.50 to $5.30 and set an outperform rating on the stock in a research note on Tuesday, May 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. Sientra currently has an average rating of Buy and a consensus target price of $6.13.

SIEN stock opened at $3.87 on Friday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.72 and a current ratio of 2.24. The company’s 50-day simple moving average is $3.79 and its 200 day simple moving average is $4.65. Sientra has a 52 week low of $1.00 and a 52 week high of $9.71. The company has a market capitalization of $192.63 million, a PE ratio of -1.48 and a beta of 1.45.

Sientra (NASDAQ:SIEN) last released its quarterly earnings results on Monday, May 11th. The medical instruments supplier reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.08). Sientra had a negative net margin of 134.87% and a negative return on equity of 101.94%. The business had revenue of $16.93 million during the quarter, compared to analyst estimates of $18.70 million. On average, analysts forecast that Sientra will post -1.64 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. UBS Group AG boosted its stake in shares of Sientra by 1.3% in the 1st quarter. UBS Group AG now owns 2,428,229 shares of the medical instruments supplier’s stock valued at $4,832,000 after purchasing an additional 32,017 shares in the last quarter. Schroder Investment Management Group boosted its stake in shares of Sientra by 1.7% in the 1st quarter. Schroder Investment Management Group now owns 1,902,776 shares of the medical instruments supplier’s stock valued at $3,863,000 after purchasing an additional 31,763 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Sientra by 966.9% in the 1st quarter. JPMorgan Chase & Co. now owns 1,154,898 shares of the medical instruments supplier’s stock valued at $2,297,000 after purchasing an additional 1,046,648 shares in the last quarter. UBS Asset Management Americas Inc. boosted its stake in shares of Sientra by 2.2% in the 4th quarter. UBS Asset Management Americas Inc. now owns 1,066,378 shares of the medical instruments supplier’s stock valued at $9,533,000 after purchasing an additional 22,925 shares in the last quarter. Finally, Granahan Investment Management Inc. MA boosted its stake in shares of Sientra by 6.6% in the 1st quarter. Granahan Investment Management Inc. MA now owns 809,972 shares of the medical instruments supplier’s stock valued at $1,612,000 after purchasing an additional 50,247 shares in the last quarter. Institutional investors own 76.99% of the company’s stock.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names.

Read More: Understanding Average Daily Trade Volume

Get a free copy of the Zacks research report on Sientra (SIEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.